Introduction
Chromosomal translocations involving chromosomal band 11q23 are the single most common cytogenetic abnormality in infants with acute leukemia, regardless of the phenotype (Kaneko et al., 1988; Gibbons et al., 1990; Martinez-Climent et al., 1995; DiMartino and Cleary, 1999) . The mixed lineage leukemia gene (MLL, also known as HRX, ALL-1 and Htrx) located at 11q23 is involved in translocations with over 40 different chromosomal bands in a variety of leukemia subtypes (Rowley, 1999) . All translocation breaks in MLL occur in an 8.3 kb BamHI genomic segment named the breakpoint cluster region (BCR), encompassing exons 8-14 (numbering according to Nilson et al., 1996; Thirman et al., 1993) .
MLL is a large protein with an estimated molecular mass of 430 kDa. The amino-terminus of MLL contains three AT-hook motifs, a transcriptional repression domain and a region of homology to mammalian DNA methyltransferase, all of which are retained in each MLL fusion protein found to date (Gu et al., 1992; Tkachuk et al., 1992; Zeleznik-Le et al., 1994) . The carboxy-terminal half of the MLL protein contains the plant homeobox domain (PHD) and the SET domain (Su(var)3-9, enhancer of zeste and trithorax), which are highly homologous to similar domains found in the Drosophila protein, trithorax (trx). The trx protein is a positive regulator of homeotic genes that are required for normal embryonic and adult development of Drosophila (Breen and Harte, 1993) . The heterozygous Mll mutant mice show abnormal expression of some of the Hox genes, providing further evidence that MLL is the mammalian homolog of trx (Yu et al., 1995) . In addition, the expression of many Hox genes is not properly maintained in embryonic fibroblasts derived from Mll homozygous mutant mice (Hanson et al., 1999) .
The mechanism of action of the MLL fusion proteins in the development of leukemia is unclear. At present, 30 different partner genes to which MLL is fused by translocations have been cloned as an initial step to elucidate the mechanism of leukemogenesis caused by the 11q23 translocations (Ayton and Cleary, 2001 ). The partner proteins do not share any distinct common sequence motif and are functionally diverse, ranging from potential nuclear transcription factors to cytoplasmic structural proteins.
Present evidence indicates that the fusion proteins formed by translocations involving the MLL gene play an important role in leukemogenesis. MLL translocations always yield in-frame fusion mRNA where the 5 0 portion of MLL is fused to different partner genes, giving rise to novel fusion genes and proteins (Rowley, 1993; Thirman et al., 1993; Bernard and Berger, 1995; Waring and Cleary, 1997) . In a murine bone marrow immortalization system, the MLL partner genes ENL, ELL and CBP were critical for immortalization and leukemogenesis (Lavau et al., 1997 (Lavau et al., , 2000a . Thus, it is clear that the partner genes contribute to the leukemogenic ability of the MLL fusions but their exact role is still not determined. Most of the common MLL translocations have been cloned. Studying the rare but recurrent translocations such as t(11;15) may offer some insight regarding the role of MLL partner genes.
Here we report on our analysis of a rare but recurring translocation, t(11;15)(q23;q14), from an 11-year-old boy with acute myeloblastic leukemia (AML-M2). This translocation has been described in a small subset of cases of both AML and ALL (Raimondi et al., 1989; Hunger et al., 1993; Thirman et al., 1993; Rubnitz et al., 1994; Hernandez et al., 1995; Hayette et al., 2000) . MLL involvement in this case was confirmed previously by Southern hybridization (Thirman et al., 1993) . Recent studies have shown that MLL is fused to AF15q14 in t(11;15)(q23;q14) (Hayette et al., 2000) . Here, we confirm the presence of the MLL-AF15q14 fusion in our patient sample. In addition to the MLL-AF15q14 fusion transcript, we have cloned another fusion transcript from the same patient sample in which MLL is fused to a novel gene, MLL partner containing FYVE domain (MPFYVE).
Results
An 11-year-old boy with de novo AML-M2 had a complex karyotype of 46,XY(18 cells)/47,XY, del(4) (q2?3q2?8),dic(6;17)(q27;p11),del(7)(p13p21), À15,t(11;15) (q23;q14),t(12;12)(q13;q23),+mar1, +mar2, +mar3(3 cells)/NCA: similar to clone 1, À9,À18, À21, Àdic(6;17) (1 cell). MLL involvement in the t(11;15)(q23;q14) was shown by a Southern blot analysis using genomic DNA from the bone marrow cells collected at the time of relapse (Thirman et al., 1993) .
At the time of initiation of this study, cloning of the MLL partner gene AF15q14 was reported in an abstract (Kuefer et al., 1997) . We received partial sequence information of AF15q14 from Dr Steve Morris (St Jude Hospital, TN, USA). After performing nested PCR with the MLL top primer, MLL 5NP, and an AF15q14 bottom primer, AF15 NP2, a distinct 400 bp amplified product was obtained (data not shown). Sequencing this product revealed that the MLL exon 8 sequences were fused to 260 bp of unknown sequence (Figure 2 ). This new sequence failed to match any known gene in the database including what was known of the AF15q14 sequence at the time. Analysis of the 400 bp chimeric cDNA amplified product showed that an open reading frame was maintained after the MLL sequence, thus potentially encoding a novel fusion protein. The breakpoint in MLL results in the loss of the final 8 nt from the 3 0 end of MLL exon 8.
To confirm that this 400 bp amplified product was not an artefact, we directly amplified the fusion from patient material using the MLL exon 8 primers, and either bottom primer B1 or B2 designed using the sequence derived from the 400 bp product (Table 1, Figures 1 and  2) . After nested PCR, we obtained products of the expected sizes of 360 and 240 bp, respectively (Figure 3a) . The sequence of the PCR products matched perfectly the sequence of the 400 bp product obtained earlier, confirming that the 400 bp PCR product cloned initially was derived from the chimeric cDNA and was not a PCR artefact. BLAST search of the EST database identified a set of ESTs that were homologous to the novel sequence fused to MLL. We sequenced two ESTs, T74136 (1.2 kb) and AI191114 (2 kb), to identify the cDNA sequence of the gene fused to MLL. The sequence comparison of the two ESTs and the fusion cDNA revealed that they were alternative splice products of the same gene (Figure 1b) . RT-PCR using RNA isolated from the cell line U937 and different primers within the EST sequence gave a variety of alternatively spliced products including one similar to the fusion transcript (data not shown).
EST AI 191114 contained almost the full-length cDNA, but it is an incompletely processed transcript containing intronic sequence at its 5 0 end. By comparing the genomic sequence of the region available in the database with our cDNA sequence (GenBank accession number AF 445414), we predicted that MPFYVE contains 12 exons and spans 10 kb of genomic DNA To evaluate the expression pattern of MPFYVE, we probed a multiple tissue Northern blot with DNA amplified from the 3 0 end of the EST T74136. A major transcript of 1.35 kb was expressed in heart (H), skeletal muscle (S), kidney (K) and liver (L) (Figure 4a ). Minor transcripts of 2.4 and 4.0 kb were also detected. A Northern blot containing total RNA from two different hematopoietic cell lines probed with the same probe showed multiple transcripts ranging from 1.35 to 4.0 kb (Figure 4b ). The size of transcripts detected with the MPFYVE probes is different from that of AF15q14 (8 and 9.5 kb), indicating that these are two different genes. Probes from EST AI191114 and the RT-PCR products obtained earlier gave the same expression pattern and transcript sizes (data not shown).
As an independent confirmation of MLL-MPFYVE fusion transcript expression, we used total RNA isolated from patient material for RNase protection analysis.
The MLL-MPFYVE fusion fragment, originally isolated by RT-PCR, was protected in the presence of patient RNA, confirming the existence of the MLL-MPFYE transcript in our patient ( Figure 4d , lane 1). We also confirmed expression of normal MPFYVE in this same sample ( Figure 4d , lane 1). The human b-actin probe was used as a control for the quality of the patient RNA (lane 4).
MPFYVE encodes a predicted protein of 48 kDa ( Figure 5a ). The translation start codon is in the second exon. The predicted amino-acid sequence showed no striking homology to any of the known proteins in the database but showed the presence of an FYVE domain near its amino-terminus within exon 3. The FYVE domain was detected using the NCBI's Conserved Domain (CD) database search. We named the new gene that is fused to MLL as MLL partner containing a FYVE domain (MPFYVE).
The predicted MLL-MPFYVE fusion protein contains the AT-hooks and the repression domain of MLL with P 1334 of MLL fused to P 73 of MPFYVE (Figure 5b ). The predicted MLL-MPFYVE fusion protein does not retain the FYVE domain of MPFYVE. The MLL-MPFYVE fusion transcript isolated from the patient material is an alternatively spliced form of the MPFYVE gene and is capable of encoding a 1435 aa protein with a predicted molecular mass of 160 kDa.
To determine whether or not we could detect a fusion of MLL and AF15q14 in our patient, we performed RT-PCR using the other downstream primers of AF15q14, AF15 6104B and AF15 7421B and MLL exon 8 top
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183 CAA AAG CCC AGC ACT TCC CAG AGC CAG GGA CTG ACA CGA CAA GAC 227 60 MLL is fused to AF15q14 and MPFYVE V Chinwalla et al primers (Table 1 and Figure 1) . Surprisingly, on the second round of amplification, we obtained 500 and 1.8 kb products, respectively (Figure 3b ). Cloning and sequencing these products showed that the MLL exon 9 is fused to exon 12 of AF15q14. Figure 5c ). The entire MLL-AF15q14 coding sequence is 5658 bp and encodes a 1886 aa chimeric protein with a predicted molecular mass of 208 kDa.
The genomic breakpoint of the t(11;15) from our patient was cloned to identify the exact break in MLL and AF15q14. Long-range PCR using genomic DNA isolated from the bone marrow cells from our patient and the MLL intron 9 top primer (MLL F4) and AF15q14 bottom primer (AF15 6084B) amplified a 1.8 kb band that was sequenced to obtain the exact sequence of the fusion junction between MLL and AF15q14 (Figure 3c ). Genomic PCR using MLL top primers and MPFYVE bottom primers did not amplify any fragment, indicating that there is only one genomic breakpoint. The two different fusions we see here could be due to alternative intragenic splicing between AF15q14 and MPFYVE.
The sequence of the BACs containing AF15q14 and MPFYVE is available in the database (AC022405 and AC012476, respectively). The position of the two genes within each BAC is known, as is the fact that these two BACs overlap each other by 10 kb. We could therefore estimate that the distance between the two genes is (Figure 1d ). By fluorescence in situ hybridization (FISH) using these BACs, we have determined that AF15q14 is centromeric to MPFYVE on chromosome 15 (Figure 6b ). The karyotype of this patient is complex and contains a deleted chromosome 15 and three marker chromosomes. There is no normal chromosome 15. Our FISH analysis with the AF15q14 BAC showed that it hybridizes to three different chromosomes, the der(11), der(15), which is the deleted chromosome 15 and a marker chromosome; the probe is duplicated on the marker chromosome. Thus, there appears to be a duplication of AF15q14. The whole chromosome paint 15 (WCP15) confirmed the presence of chromosome 15 sequences on the marker chromosome to which the AF15q14 BAC hybridizes (data not shown). Hybridization of the AF15q14 probe to der(11), deleted chromosome 15 and the marker chromosome with chromosome 15 sequences, indicates that it contains the breakpoint of t(11;15) ( Figure 6a ). The MLL probe also gave a split signal between the der(11) and der(15) chromosomes, confirming the involvement of MLL in this case; the critical 5 0 MLL-3 0 AF15q14 fusion is on the der(11) chromosome. Different MPFYVE containing BACs did MLL is fused to AF15q14 and MPFYVE V Chinwalla et al not show a split signal; instead the entire MPFYVE signal was translocated to the der(11), indicating that MPFYVE is telomeric to AF15q14 (Figure 6b) . Moreover, the MPFYVE containing BACs only gave one signal on the marker chromosome, indicating that the MPFYVE gene is not duplicated. The importance of the AF15q14 duplication is not currently understood.
Discussion
Cloning the chimeric cDNA and genomic breakpoint junction formed by the t(11;15) from this patient reveals a complex situation. We have identified two in-frame fusions in which the 5 0 portion of MLL is fused to a novel gene, MPFYVE, and a recently identified gene, (red) showed three signals, on normal 11, der(11) (arrowhead) and der(15) (arrow). MPFYVE BACs showed only two signals (green): marker chromosome which is a normal chromosome 15 and der(11) where the entire BAC was translocated, telomeric to MLL. This indicates that the genomic break is 5 0 of MPFYVE. (b) FISH analysis using AF15q14 and MPFYVE BACs as probes. The AF15q14 BAC (red) showed three signals, on der(11) (arrowhead), der(15) (short arrow) and a marker chromosome, which contains chromosome 15 sequences. The AF15q14 probe is duplicated on the marker chromosome as seen by the presence of two red signals (long arrow). The MPFYVE probe (green) labels the der(11) and has a single signal on the marker chromosome AF15q14. The two putative fusion proteins retain the AT-hooks, DNA methyltransferase homology and the repression domains of MLL. In the MLL-MPFYVE fusion, MLL exon 8 (minus 8 nt from the 3 0 end of the exon) is fused to MPFYVE exon 4. Since the site of fusion of MLL with MPFYVE is within an exon, it could be a cryptic splice donor site/acceptor site enabling the fusion to maintain its open reading frame. Usage of cryptic splice donor and acceptor has been well documented in MLL fusions (Caldas et al., 1998; Divoky et al., 2000) . Although canonical splice donor/ acceptor sequences are not present at the fusion junction, we are confident that this is the real junction sequence. We have independently PCR amplified this junction using different primer pairs and sequenced the PCR products both directly and after subcloning. Further data supporting the existence of MLL-MPFYVE fusion RNA come from the RNase protection assay (Figure 4d ). Another interesting observation of the fusion RNA is that the 7 nt at the junction between MLL and MPFYVE are identical. The importance of this 7 bp homology at the point of fusion is unclear. Furthermore, the genomic break in MLL is in intron 9, but the MLL-MPFYVE fusion did not contain exon 9. This is likely owing to alternative splicing of MLL exon 9, which has been previously described.
MPFYVE encodes a small protein containing 438 amino acids. The MPFYVE protein does not share extensive homology to any previously identified proteins but contains a highly conserved FYVE domain near its amino-terminus. The FYVE domain is a zinc-finger motif, which is conserved among many yeast, Caenorhabditis elegans and mammalian proteins (Figure 7) . It was named 'FYVE' after four proteins (Fab1p, YOTB, Vac1p and EEA1) containing this motif (Stenmark et al. 1996) . The FYVE domain contains eight conserved cysteines, which coordinate two Zn 2+ ions (Schwabe and Klug, 1994; Stenmark et al., 1996) . In addition to the cysteines, the R(R/K)HHCRxCG motif surrounding a third and a fourth cysteine residue and an arginine at position 68 are also highly conserved in the family (Stenmark and Aasland, 1999) . Several proteins, such as Rabphilin 3A and Rim, lack the R(R/K)HHCRxCG motif and the arginine at position 68 and are thus characterized separately as FYVE-related domain containing proteins. These proteins contain a conserved (Stenmark and Aasland, 1999) . The FYVE domain of MPFYVE contains only six cysteines and is missing the first two cysteines present in the consensus. R+HH is absent in MPFYVE, which makes it more similar to the FYVE-related fingers. The absence of 'R+HH' is shown here by highlighting the existing residues 'lqyg' in bold. The weakly conserved hydrophobic residue at position 67 is not conserved in MPFYVE (numbering specific to this figure). Arginine to lysine at position 68 is a conservative change and therefore may not change the structure of the finger. # strongly conserved hydrophobic; À strongly conserved acidic; + strongly conserved basic; % weakly conserved hydrophobic. (b) FYVE-related fingers. The MPFYVE sequence is aligned with the known FYVE-related fingers described by Stenmark and Aasland (1999) . Like other FYVE-related fingers, MPFYVE lacks the R+HH motif, but still contains the glycine residue (bold) at a conserved position 39 (numbering specific to this figure) similar to the FYVE domain glycine at position 39. The FYVE domain of MPFYVE resembles the FYVE-related domain as it lacks the R(R/ K)HHCRxCG motif and the arginine at position 68. MPFYVE contains only six cysteines instead of eight and hence represents a variant member of this family.
Most of the FYVE domain proteins are involved in endosomal trafficking of proteins, but some are also shown to be involved in other cellular processes, such as signal transduction and cytoskeletal regulation (reviewed by Stenmark and Aasland, 1999) . The FYVE domain has been shown to bind to phosphotidylinositol-3 phosphate (PtdIns(3)P) in the basic pocket created by the R(R/K)HHCRxCG motif (Burd and Emr, 1998; Gaullier et al., 1998; Patki et al., 1998; Stenmark and Aasland, 1999) . Proteins containing the FYVE-related domain contain fewer basic residues in this pocket area and only one of them is conserved (position 39, Figure 7) . Therefore, it is predicted that these proteins bind to a less acidic or a neutral ligand. Proteins containing the FYVE-related domain play roles in regulated secretion. The MPFYVE protein contains the variant form of the FYVE-related domain and future functional tests will determine if it plays a role in regulated secretion as do the other members of the family.
The second fusion we have identified is MLLAF15q14 in which the AF15q14 exon 12 is fused to MLL exon 9. The breakpoint in AF15q14 reported here is different from the two published breaks in AF15q14 (Hayette et al., 2000, Kuefer et al., this issue) . The break in AF15q14 in both cases is in exon 11. The MLLAF15q14 fusion protein described by Hayette et al. contains only 85 amino acids of AF15q14, out of which 43 are encoded by exon 11. The remaining amino acids are unique to the AF15q14 sequence described by Hayette et al. and are not present in the sequence reported by Kuefer et al. (this issue) . The fusion described here and by Kuefer et al. contains amino acids encoded by exon 12 and further 3 0 of AF15q14. Therefore, the AF15q14 amino-acid sequence of the chimeric proteins studied here and by Kuefer et al. is completely different from that present in the fusion described by Hayette et al. The presence of two different fusion transcripts in which MLL is fused to two different genes is unique to the patient we studied. We analysed RNA from the t(11;15) patient sample studied by Kuefer et al. and could not amplify an MLL-MPFYVE fusion from that patient material.
In the leukemia cells we studied here, the genomic break is in intron 9 of MLL, and in intron 11 of AF15q14. There is only one genomic break on chromosome 15. The presence of two different rearranged transcripts of MLL has been observed in other cases where MLL tandem duplication is present along with the MLL-AF9 fusion transcript (Whitman et al., 2001) . The two different fusion transcripts we cloned here may be the result of intragenic splicing. Although such intragenic splicing has not been observed for MLL fusions before, it has been reported in a t(3;21) translocation (Nucifora et al., 1994) . In the case of the t(3;21), the AML1 gene on chromosome 21 is fused to three genes EAP, MDS1 and EVI1, which are separated from each other over a distance of approximately 450 kb. The two genes AF15 and MPFYVE are only 170 kb apart, with MPFYVE being telomeric to AF15q14 (Figure 1d ).
The presence of two different MLL fusion transcripts raises an important question as to which of the two transcripts (or both) are important for leukemia. Future experiments using the two fusions in retroviral transduction of murine bone marrow progenitors will be able to address this question.
Materials and methods

Patient material
Leukemic cells from an 11-year-old male with de novo AML-M2 had a t(11;15)(q23;q14). Cytogenetic analysis at diagnosis was unsuccessful because of inadequate material. The patient relapsed after 1 year and cytogenetic analysis of the metaphase chromosomes revealed a t(11;15)(q23;q14) as one of the cytogenetic abnormalities. This patient material was obtained with informed consent.
Cloning of the chimeric cDNA using 3 0 rapid amplification of cDNA ends (RACE) Total RNA from a frozen bone marrow sample collected at the time of relapse was extracted using Tri Reagent (Molecular Research Corp., Cincinnati, OH, USA) according to the manufacturer's guidelines. The first strand of cDNA was made with 2 mg of total RNA using the Adapter primer following the specifications outlined by the Gibco-BRL 3 0 RACE kit (Gaithersburg, MD, USA). Polymerase chain reaction (PCR) was used to amplify the putative fusion transcript using the MLL exon 8 top primer MLL 5A (Table 1, Figure 1 ) and the abridged universal amplification primer (AUAP) provided in the kit. One-tenth of the first strand cDNA reaction was used to synthesize the second strand in a standard PCR. The nested PCR was carried out using 1/30th of the first round PCRamplified DNA, MLL 5NP and AF15 NP2 (Table 1, Figure 1) .
The PCR products were resolved by electrophoresis on a 1% TAE-agarose gel, purified using Gene Clean Extraction Kit (BIO 101, Vista, CA, USA) and cloned in a TA cloning vector (Invitrogen, Carlsbad, CA, USA). Sequencing reactions used the ABI PRISM dye Terminator cycle sequencing Reaction Ready kit (Perkin-Elmer, Foster City, CA, USA), following the manufacturer's specifications. Gel electrophoresis, data collection and analyses were performed with an automated sequencer (Model 377A, Applied Biosystems, Foster City, CA, USA). Searches for sequence similarity were performed with the GenBank nucleic acid databases using the BLAST program (Adams et al., 1991) .
Reverse transcription (RT)-PCR
One-tenth of the first strand cDNA synthesized for the 3 0 RACE protocol was used as a template to amplify the chimeric cDNA product using MLL top primers and the gene-specific bottom primers as follows:
Amplification of the MLL-MPFYVE fusion transcript A different MLL exon 8 top primer (MLL 5UNP) and either MPFYVE bottom primers B1 or B2 were used in the first round PCR (Table 1, Figure 1) . The nested PCR used 1/30th and 1/300th of the amplified DNA from first round, MLL 5NP with either NB1 or NB2. The cycling conditions used were 2 min at 941C, 30 cycles of 30 s at 941C, 2 min at 581C, 2 min at 721C and final extension at 721C for 7 min.
Amplification of the MLL-AF15q14 fusion transcript MLL 5A and the AF15 6104B or AF15 7421B with an annealing temperature of 601C were used in the first round of PCR amplification (Table 1, Figure 1) . One-thirtieth of the first round PCR-amplified DNA with nested primers MLL 5NP and the AF15 6084B or 7366B were used to amplify the RT-PCR products (Table 1, Figure 1) , respectively. The numbers of the AF15 primers refer to the position in the nucleotide (nt) sequence. The RT-PCR products were purified by gel electrophoresis using 1.5% TAE-agarose, cloned into TA cloning vector and sequenced as described above.
Long-range genomic PCR
Genomic DNA from the bone marrow sample of the patient was isolated (Puregene DNA isolation kit, Gentra Systems, Minneapolis, MN, USA), following the manufacturer's instructions. Long-range PCR (TaqPlus Long PCR system, Stratagene, La Jolla, CA, USA) was performed using 300 ng genomic DNA, 1 Â high-salt buffer, 200 nm of primers MLL F4 and AF15 6084B, 200 mm each of dATP, dCTP, dTTP, dGTP and 5 U of TaqPlus Long polymerase. The cycling conditions used were 2 min at 941C, 30 cycles of 30 s at 941C, 1 min at 601C, 5 min at 721C and final extension at 721C for 7 min. The amplified fragment was purified and sequenced using the MLL F4 primer.
Isolation of BACs containing AF15q14 and MPFYVE
A BAC library, containing human genomic DNA (Research Genetics, Huntsville, AL, USA), was screened using the manufacturer's guidelines to isolate genomic clones containing the AF15q14 and the MPFYVE genes. BAC 21B18 containing the AF15q14 gene was isolated using primers AF15 T and AF15 P2. BACs 164E2 and 147G20 containing MPFYVE were isolated using primers NG 32 T and NG 406B (Table 1, Figure 1 ).
Purified BAC DNA was prepared using the Qiagen largescale plasmid kit. DNA isolated from these BACs and the DNA from the BACs used for sequencing in the database (534F12 and 2339L15) were used as probes in fluorescence in situ hybridization (FISH) of patient chromosomes. A previously published probe for MLL from ONCOR was used.
Northern blot analysis
The human multiple tissue Northern blot was purchased from Clontech Inc. (Palo Alto, CA, USA). The prehybridization and hybridization were performed according to the manufacturer's protocol using the expressed sequence tag (EST) clones containing the MPFYVE sequences as probes.
RNase protection assay
The MLL-MPFYVE RT-PCR fragment cloned into PCR2.1 cloning vector (Invitrogen, Inc.) was used to make an antisense RNA probe using T7 RNA polymerase. The probe was synthesized by in vitro transcription, using the guidelines and reagents of a Maxiscript kit from Ambion Inc. (Austin, TX, USA) and biotin-labeled UTP (Roche). The RNase protection assay was performed using the procedure described in the RPA III kit (Ambion Inc.). The purified MLL-MPFYVE probe (264 pg) was hybridized with 20 ml of total RNA from the patient sample, overnight at 42 o C. Two separate controls with the same amount of probe as test and 10 mg of yeast RNA each were set up. One of the yeast RNA tubes was treated with RNase at the end of hybridization similar to the test sample, and the other was not (intact probe). The yeast RNA sample that was treated with RNase is a control for RNase digestion. A human b-actin RNA probe (250 pg) was used to hybridize with 10 ml of patient RNA as a control for quality of RNA. After RNase digestion, the samples were run on a 5% polyacrylamide/8 m urea gel, transferred onto a nylon membrane (Ambion, Inc.), using electroblotting and 1 Â TBE buffer (BioRad, Inc., CA, USA) at 80 mA for 1 h. The blot was then processed using BrightStar BioDetect, a nonisotopic detection kit from Ambion, Inc., following the manufacturer's guidelines.
